226 filings
Page 7 of 12
6-K
3qe4x9ssb
9 Jun 20
Current report (foreign)
4:10pm
6-K
hyrngmgokyffa gqk32
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
2fkw vslosbq8xzpw5
8 May 20
ObsEva Annual General Meeting 2020
4:38pm
6-K
9qjwz6cwzizp9z
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
ohiimn
23 Apr 20
ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis
4:00pm
6-K
z31e0qrqx mix5kprc
14 Apr 20
ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares
6:41am
6-K
trh5mt3n
7 Apr 20
Current report (foreign)
5:30pm
6-K
o8jqh3
6 Apr 20
ObsEva SA Announces New Interim Chief Financial Officer
4:00pm
6-K
epycbmv3oqs4d
27 Mar 20
Current report (foreign)
7:19am
6-K
j3j9msip
23 Mar 20
ObsEva Provides Update Related to COVID-19 Pandemic
4:00pm
6-K
779vbhrfb4
5 Mar 20
Current report (foreign)
4:10pm
6-K
nohrxzmbu3ans
15 Jan 20
Current report (foreign)
8:35pm
6-K
9rmc u4785
10 Dec 19
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
12:00am
6-K
knd18frif
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
6-K
lohvguf3l b6a
7 Nov 19
Current report (foreign)
9:11am
6-K
b3y49nvjmtetv6s
31 Oct 19
ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical
4:21pm
6-K
4hzbz 6pow
12 Sep 19
ObsEva announces new composition of its Executive Committee
8:16am
6-K
9tb e5xflwhogc
6 Sep 19
ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of
8:27am
EFFECT
ybuzh32o4bga8h39j
15 Aug 19
Notice of effectiveness
12:15am